|
R. Chad Wade, MD1,2 Sarah Robison, MD1,2 J. Michael Wells, MD1,2 Takudzwa Mkorombindo, MD1 Maida Chaudhry, MD1 Mohamed Kheder Aly Awad, MD1 Young-il Kim, PhD1 Kaiyu Yuan, MD1 Mohamed Mohsen Abdalla, BS1 Mark T. Dransfield, MD1* Steven R. Duncan, MD1*
Author Affiliations
- Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
- Birmingham VA Healthcare System, Birmingham, Alabama, United States
*Equal contributions
Address correspondence to:
Steven R. Duncan, MD
Department of Medicine
University of Alabama at Birmingham Medical Center
1900 University Blvd., Birmingham, AL 35294
Phone: (205) 934-5017
Email: srduncan@uabmc.edu
Abstract
Background: We hypothesized autoantibodies with specificity for glucose-regulated protein 78 (anti-GRP78), a ubiquitous heat shock protein and key component of the unfolded protein response, are associated with development of cardiovascular disease (CVD) in chronic obstructive pulmonary disease (COPD) patients. Treatments focused on the underlying autoimmune processes reduce CVD events in those afflicted with connective tissue diseases, but analogous therapies have not yet been tested in COPD patients, in whom atherosclerotic disease is a significant cause of mortality.
Methods: Plasma anti-GRP78 immunoglobulin G was measured by enzyme-linked immunosorbent assay in 2 independent cohorts of COPD participants who had coronary artery calcium (CAC) determinations by chest computed tomography. Another COPD cohort was randomized to belimumab (10mg/kg intravenously every 2 weeks × 3, followed by 5 monthly infusions) (n=10) or placebo (n=6). The primary endpoint was changes of circulating anti-GRP78 levels.
Results: Anti-GRP78 levels in COPD patients (n=37) were highly correlated with CAC scores (rs=0.56, p<0.001). Autoantibody concentrations were reduced by ~17% (from 0.50+0.11 to 0.40+0.09 optical density units, p=0.02) but unchanged by placebo (p=0.75), and the reductions were proportionate to pretreatment autoantibody levels (rs=-0.65, p=0.05). There were no reductions of protective antipneumococcal antibody levels or serious adverse events definitively attributable to belimumab treatment.
Conclusions: Belimumab therapy reduces circulating anti-GRP78 autoantibodies, which have been linked to CVD and other COPD comorbidities. Autoantibody reduction may be a novel approach to mitigate COPD-associated comorbidities. These findings support a larger trial to thoroughly assess the efficacy and safety of belimumab, or other specific autoimmune-targeted therapies, in COPD patients with CVD.
Trial Registration: clinicaltrials.gov: NCT03244059
Citation
Citation: Wade RC, Robison S, Wells JM, et al. A phase 2b randomized trial of belimumab to reduce atherogenic autoantibodies in COPD patients. Chronic Obstr Pulm Dis. 2026; 13(6): 440-451. doi: http://dx.doi.org/10.15326/jcopdf.2026.0805
|
Robert J. Kaner, MD1,2 Sarah L. O’Beirne, MD, PhD1,2* Amy Krambrink, MS3 Cathie Spino, ScD3 He S. Yang, PhD4 Yuan-Shan Zhu, BM, PhD5,6 Ronald G. Crystal, MD1,2 Marshall J. Glesby, MD, PhD7
Author Affiliations
- Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, New York, United States
- Department of Genetic Medicine, Weill Cornell Medicine, New York, New York, United States
- Statistical Analysis of Biomedical and Educational Research Group, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, United States
- Clinical and Translational Science Center, Weill Cornell Medicine, New York, New York, United States
- Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, New York, United States
- Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States
* Current affiliation: University College, Dublin, Ireland
Address correspondence to:
Robert J. Kaner, MD
1300 York Avenue, Box 164
Weill Cornell Medicine
New York, NY 10065
Email: rkaner@med.cornell.edu
Abstract
Rationale: Emphysema is prevalent in smoke-exposed people living with HIV (PLWH). Matrix metalloproteinases (MMPs) are increased in bronchoalveolar lavage (BAL) fluid in PLWH with emphysema. Doxycycline is a U.S. Food and Drug Administration-approved MMP-9 inhibitor, in addition to its antimicrobial properties.
Objectives: We aimed to test the safety and tolerability of doxycycline in PLWH.
Methods: We created a single center, double-blind, randomized, placebo-controlled (2:1) pilot study of doxycycline 100mg orally twice daily in 27 PLWH who have chronic obstructive pulmonary disease and/or emphysema (NCT01744093).
Measurements and Main Results: Our results revealed that doxycycline was safe and well-tolerated. There were robust serum and BAL fluid levels of doxycycline in individuals assigned to the doxycycline arm. Preliminary evidence of potential biologic effects of doxycycline in the lung included a reduction in BAL lung lymphocytes and a trend toward decreased MMP-9 activity.
Conclusions: These data provide a rationale for a phase 2, 72-week randomized placebo-controlled trial of doxycycline to slow the progression of emphysema in PLWH (NCT05382208).
Citation
Citation: Kaner RJ, O’Beirne SL, Krambrink A, et al. Randomized double-blinded pilot study of doxycycline for HIV-associated COPD and emphysema. Chronic Obstr Pulm Dis. 2026; 13(6): 452-462. doi: http://dx.doi.org/10.15326/jcopdf.2026.0796
|
Changfang Geng, RN1 Quan Gao, RN1 Jia Yu, RN1 Wei Huang, RN1
Author Affiliations
- Department of Respiratory and Critical Care Medicine, Liyang Branch Hospital of Jiangsu Province Hospital, Liyang, Jiangsu, China
Address correspondence to:
Wei Huang
Department of Respiratory and Critical Care Medicine
Liyang People’s Hospital
No. 70 Jianshe West Road
Liyang, Jiangsu 213300
China
Phone: +86-13815084002
Email: huangwei6788@163.com
Abstract
Background: Chronic obstructive pulmonary disease (COPD) causes dyspnea and impaired function. Evidence for structured nurse-led pursed-lip breathing (PLB) plus abdominal breathing (AB) in stable outpatients is limited.
Methods: In this single-center randomized controlled trial, 218 adults with Global initiative for chronic Obstructive Lung Disease (GOLD) stage 2–4 stable COPD were randomized 1:1 to 12 weeks of nurse-led PLB plus AB or routine care. Coprimary outcomes were changes in forced expiratory volume in 1 second (FEV1) and 6-minute walk distance (6MWD). Secondary outcomes were forced vital capacity (FVC), FEV1/FVC, COPD Assessment Test (CAT) score, peripheral oxygen saturation (SaO2), and modified Medical Research Council dyspnea scale grade. Intention-to-treat analysis of covariance was performed, adjusting for baseline, age, sex, and GOLD stage, with multiple imputation for missing data.
Results: At week 12, adjusted differences favored the intervention for FEV1 (0.14L; 95% confidence interval [CI], 0.11–0.17), 6MWD (37.8m; 95% CI, 31.5–44.1), FVC (0.16L; 95% CI, 0.11–0.21), CAT score (−4.22 points; 95% CI, −4.90 to −3.54), and SaO2 (1.33 percentage points; 95% CI, 1.10–1.56) (all P<0.001). FEV1/FVC change was not significant (P=0.095). Adherence was 87.2%; no intervention-related adverse events were reported.
Conclusions: Nurse-led PLB plus AB improved spirometric outcomes, functional exercise performance, symptoms, and oxygenation. Multicenter trials with stronger adherence, medication, and mechanistic assessments are needed.
Citation
Citation: Geng C, Gao Q, Yu J, Huang W. Nurse-led pursed-lip and abdominal breathing training improves pulmonary function and functional exercise performance in patients with chronic obstructive pulmonary disease: a prospective randomized controlled trial. Chronic Obstr Pulm Dis. 2026; 13(6): 463-470. doi: http://dx.doi.org/10.15326/jcopdf.2026.0851
|
Anat Romem, RN, NP, DNP1,2 Ayal Romem, MD, MHA3,4
Author Affiliations
- Henrietta Szold School of Nursing, Faculty of Medicine, Hadassah, The Hebrew University of Jerusalem, Jerusalem, Israel
- Herzog Medical Center, Jerusalem, Israel
- Department of Pulmonology, Meir Medical Center, Kfar Saba, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Address correspondence to:
Anat Romem, RN, NP, DNP
Henrietta Szold School of Nursing
Faculty of Medicine, Hadassah, The Hebrew University of Jerusalem
Jerusalem, Israel
Phone: +972-54-7038334
Email: anat.romem@mail.huji.ac.il; anatromem1234@gmail.com
Abstract
Background: Advanced chronic obstructive pulmonary disease (COPD) is associated with substantial multimorbidity and hospital-based care near the end of life. We described multimorbidity, acute-care utilization, and documented palliative care exposure among older decedents with advanced COPD.
Methods: We conducted a retrospective population-based cohort study using routinely collected data from an integrated health system. The cohort included eligible decedents aged 55 years or older with advanced COPD who died during 2016–2020 and 2022–2023; 2021 was excluded because the COVID-19 pandemic disrupted usual utilization patterns. Multimorbidity was characterized using the age-adjusted Charlson Comorbidity Index (CCI), comorbidity count, and individual conditions. Outcomes included total hospital admissions, hospitalizations per patient, emergency department visits, intensive care unit days, hospitalization duration, procedure burden, and documented palliative care exposure during the final year of life.
Results: The cohort included 2261 decedents. Mean age at death was 77.75 years, mean age-adjusted CCI was 8.73, and mean comorbidity count was 4.05. A total of 9489 hospital admissions were recorded; the mean was 4.74 hospitalizations per patient. Only 167 patients (7.4%) had documented palliative care exposure. Women were older at death, whereas men had higher mean CCI scores, comorbidity counts, and recorded procedure burden.
Conclusions: Older decedents with advanced COPD experienced substantial multimorbidity and hospital-centered acute-care use, while documented palliative care exposure was uncommon. Survival analyses by palliative care exposure were excluded because exposure timing was unavailable and fixed retrospective classification would be vulnerable to immortal-time bias.
Citation
Citation: Romem A, Romem A. Multimorbidity and acute-care use among older decedents with advanced chronic obstructive pulmonary disease: a retrospective population-based cohort study. Chronic Obstr Pulm Dis. 2026; 13(6): 471-478. doi: http://dx.doi.org/10.15326/jcopdf.2026.0807
|
Matthew Camiolo, MD, PhD1* Hitesh Pandya, MBChB, MD2 Mandeep Jassal, MD3 Artur Bednarczyk, MD4 Yubo Tan, MSc5 Margareta Puu, PhL6 David Petullo, MSc7 Patrik Bondarov, MSc8 Artur Mark-Pawlowicz, MD4 Jie Mei, MD, PhD9 Lars Pettersson, MSc9 Mehul Patel, MBBS, FRCP PhD2 MeiLan K. Han, MD, MS10
Author Affiliations
- Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States
- Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
- Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States
- Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland
- Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Mississauga, Canada
- Late Respiratory and Immunology Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States
- Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Global Patient Safety BioPharmaceuticals, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden
- Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan, United States
* Affiliation at the time of the study
Abstract
Background: The purpose of this study was to understand the efficacy, safety, and tolerability of the budesonide/glycopyrrolate/formoterol fumarate (BGF) pressurized metered-dose inhaler (pMDI) with the next-generation propellant hydrofluoroolefin-1234ze (HFO-1234ze), a propellant with substantially lower global warming potential, versus hydrofluoroalkane-134a (HFA-134a).
Methods: This randomized, 3-way crossover study (NCT06075095) assessed the pharmacodynamic equivalence and safety of BGF HFO-1234ze versus BGF HFA-134a in participants with chronic obstructive pulmonary disease. Participants received twice-daily doses for 4 weeks in 3 consecutive treatment periods: (A) BGF HFO-1234ze 320/18/9.6 μg, (B) BGF HFA-134a 320/18/9.6 μg, and (C) placebo HFA-134a in 1 of 6 randomized sequences. Two lung function endpoints (change from baseline in postdose forced expiratory volume in 1 second [FEV1] area under the curve 0–4h [ AUC0–4h; primary] and morning predose trough FEV1 [secondary] at Day 29) were assessed. Superiority of BGF HFA-134a versus placebo HFA-134a was assessed to demonstrate assay sensitivity. Propellant equivalence was demonstrated if the 2-sided 90% confidence intervals (CIs) for ratios of BGF HFO-1234ze/BGF HFA-134a for both lung function endpoints were within 0.8–1.25 and 0.7–1.43, respectively. Safety was also assessed.
Results: A total of 296 participants were randomized and started treatment. Superiority of BGF HFA-134a versus placebo HFA-134a, and thus, assay sensitivity for the effect of BGF, was confirmed for both lung function endpoints (p<0.001). Change from baseline in postdose FEV1 AUC0–4h and morning predose trough FEV1 at Day 29 were equivalent between BGF HFO-1234ze and BGF HFA-134a (ratio [90% CI]: 0.94 [0.88, 1.00]; 0.95 [0.84, 1.08], respectively). Adverse events were balanced across treatments.
Conclusion: Findings support the switch from HFA-134a to HFO-1234ze in BGF pMDIs.
Citation
Citation: Camiolo M, Pandya H, Jassal M, et al. Pharmacodynamic equivalence and safety of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a propellant: a randomized phase 3 study in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2026; 13(6): 479-488. doi: http://dx.doi.org/10.15326/jcopdf.2026.0793
|
Patricia J. Checinski, MD1 Kaitland M. Byrd, PhD2 Wassim W. Labaki, MD, MS2 Thomas S. Valley, MD, MSc3 Philip J. Choi, MD4 Elizabeth M. Viglianti, MD, MPH, MSc2,5
Author Affiliations
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan – Michigan Medicine, Ann Arbor, Michigan, United States
- Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, New York University Langone Health, New York, New York, United States
- HSR Center of Innovation, Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan, United States
Address correspondence to:
Patricia J. Checinski, MD
Vanderbilt Lung Institute
One Hundred Oaks
719 Thompson Lane, Suite OHO 30152
Nashville, TN 37204
Phone: (615) 421-6688
Email: patricia.j.checinski@vumc.org
Abstract
Background: Long-term noninvasive ventilation (NIV) improves survival and readmission risk for patients with chronic hypercapnia from chronic obstructive pulmonary disease (COPD). However, outpatient NIV prescription remains low.
Methods: We conducted a qualitative study using semistructured interviews with pulmonary physicians. We identified a convenience sample of community-affiliated outpatient pulmonologists who were recruited via email. Deductive and inductive thematic content analysis were used to identify how physicians screen and manage patients with COPD at risk for chronic hypercapnia and what barriers hinder their ability to care for this population.
Results: Among 15 physicians interviewed, 13 were general pulmonologists. Two were sleep certified. They spent 52.5 + 21.3% of clinical time on average in outpatient care. While physicians identified forced expiratory volume in 1 second and serum bicarbonate as parameters that would prompt a hypercapnia evaluation, there was no consistent threshold identified. Physicians initiated NIV themselves but varied in initial device selection and settings. Arterial blood gas testing was infrequently used to monitor improvement and opinions differed on why and how initial NIV settings needed to be changed. Barriers to management included patient factors (e.g., NIV disinterest), physician discomfort (e.g., NIV troubleshooting), poor access to testing, lack of clinical support, and insurance and durable medical equipment company logistics.
Conclusions: Pulmonary physicians face multiple barriers in caring for this population, leading to variation in screening and management practices for chronic hypercapnia in COPD. Areas for improvement include standardized screening guidance, better clinical support and testing access, improved clinical education, and a streamlined approach to insurance approval.
Citation
Citation: Checinski PJ, Byrd KM, Labaki WW, Valley TS, Choi PJ, Viglianti EM. Clinician-perceived barriers and facilitators for initiation and management of noninvasive ventilation among patients with chronic hypercapnia from COPD: a qualitative study. Chronic Obstr Pulm Dis. 2026; 13(6): 489-499. doi: http://dx.doi.org/10.15326/jcopdf.2026.0846
|
Sarah Miller, PhD, RN1 Hayley D. Germack, PhD, RN2 Meredith Bell, PharmD3 Norbert Feigler, MD3 Randy Legg, PharmD, MBA4 Kathleen Henderson5 Chip Kreisman, BSB5 Karen Winkler, MSc6 Dorsa Khazaei, MSc7 Tommi Tervonen, PhD8 Gerard J. Criner, MD9
Author Affiliations
- College of Nursing, Medical University of South Carolina, Charleston, South Carolina, United States
- U.S. Medical Evidence, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, United States
- U.S. Respiratory Medical, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, United States
- U.S. Clinical Value and Outcome, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, United States
- Patient Co-Investigator, United States
- Kielo Research, Hamburg, Germany
- Kielo Research, London, United Kingdom
- Kielo Research, Zug, Switzerland
- Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States
Abstract
Rationale: Nighttime symptoms are clinically important but understudied in chronic obstructive pulmonary disease (COPD). This study explored patients’ perceptions of nighttime symptoms, their effects on daily life, and symptom-management strategies.
Methods: Thirty U.S. adults with COPD and a moderate-to-high symptom burden (COPD Assessment Test score ≥10), without a hospitalization or emergency department visits for a severe exacerbation during the previous year, participated in semistructured interviews. All participants received single-inhaler dual or triple maintenance therapy and completed the 7-item COPD and Asthma Sleep Impact Scale (CASIS). Interviews were transcribed verbatim and thematically analyzed using the Symptom Management Theory framework.
Results: Participants (median age 63; 60% female; 90% White) reported a high burden of nighttime symptoms and sleep disruption (87% severely impacted based on CASIS). Participants described a pronounced nighttime symptom experience, most frequently shortness of breath, mucus/phlegm production, coughing, and difficulty staying asleep or frequent awakenings. A range of symptom management strategies was reported, including behavioral adaptations (routines, avoidance of technology, sleep hygiene), pharmacological management (antidepressants, sleep medications, rescue inhalers), and complementary and integrative approaches (meditation, acupuncture, relaxation techniques). Nighttime symptom outcomes extended beyond sleep disruption. Participants reported significant daytime consequences, including fatigue and impaired concentration. These effects contributed to activity avoidance and limitations in social participation.
Conclusions: Among symptomatic patients receiving single-inhaler dual or triple maintenance therapy, nighttime COPD symptoms were commonly reported and were associated with substantial physical, emotional, and functional impacts. The findings support further consideration of nighttime symptoms in clinical assessment and individualized COPD management.
Citation
Citation: Miller S, Germack HD, Bell M, et al. Nighttime symptom burden in chronic obstructive pulmonary disease: a qualitative study. Chronic Obstr Pulm Dis. 2026; 13(6): 500-512. doi: http://dx.doi.org/10.15326/jcopdf.2026.0780
|
Igor Barjaktarevic, MD, PhD1 Matthew Dartt, MBA, BSRT, RRT-ACCS2 Siyan Chen, MS3 D’Mitri Champion, MBA, RRT2 Roberto Mempin, MD1 Yongyus Dejsatha, RRT2 Joseph Van Vleet, BSRC, RRT2 Steven Y. Chang, MD, PhD1 Oscar Estrada, MD1 Timothy Young, MD1 Russell G. Buhr, MD, PhD1,4,5 Donald Tashkin, MD1 Joanne M. Bando, MD1
Author Affiliations
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States
- Respiratory Care, University of California Los Angeles, Los Angeles, California, United States
- Biostatistics, University of California Los Angeles, Los Angeles, California, United States
- Department of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States
- Center for the Study of Healthcare Innovation, Implementation, and Policy, Greater Los Angeles VA Healthcare System, Los Angeles, California, United States
Address correspondence to:
Igor Barjaktarevic, MD, PhD
Division of Pulmonary and Critical Care Medicine
David Geffen School of Medicine, University of California Los Angeles
Los Angeles, CA
Email: ibarjaktarevic@mednet.ucla.edu
Abstract
Background: Revefenacin is a nebulized long-acting muscarinic antagonist approved for maintenance therapy in stable chronic obstructive pulmonary disease (COPD). We conducted a pilot study to evaluate the feasibility and safety of revefenacin in mechanically ventilated COPD patients with acute respiratory failure (ARF) and compare its use with the short-acting muscarinic antagonist ipratropium, the current standard inpatient therapy.
Methods: In this double-blind, randomized controlled pilot study, intubated COPD patients were assigned to revefenacin 175mcg once daily plus 3 placebo doses, or ipratropium 500mcg via vibrating mesh nebulizer every 6 hours, for up to 7 days. The primary endpoints were safety and feasibility; exploratory endpoints included ventilator-derived respiratory mechanics and clinical outcomes.
Results: Of 24 randomized patients, 21 (mean age 76±11 years, 60±51 pack years smoking, forced expiratory volume in 1 second percentage predicted 56±26%) received the study drug and were included in the analysis (12 in the revefenacin group and 9 in the ipratropium group). Participants in revefenacin and ipratropium arms had similar duration of mechanical ventilation at the time of enrollment (1.3±0.8 versus 1.8±0.8, P=0.13) and had similar duration of study intervention period (2.5±2.3 versus 3.6±2.8 days; P=0.83). Daily nebulization time was significantly lower with revefenacin (7.2±1.0 versus 26.8±5.3 minutes; P<0.01). Adverse events were infrequent and comparable between the groups. Revefenacin improved dynamic resistance postdose (-0.9 versus +2.6 cmH₂O/L/s; P<0.01), without differences in peak inspiratory, resistive, or plateau pressures.
Conclusion: Once-daily nebulized revefenacin is a feasible and safe alternative to ipratropium in mechanically ventilated COPD patients with ARF, with reduced time spent on nebulization administration. Improvements in airway resistance suggest a potential physiologic benefit, warranting further investigation.
Citation
Citation: Barjaktarevic I, Dartt M, Chen S, et al. Comparison of nebulized long-acting muscarinic antagonist revefenacin to ipratropium in COPD patients with acute respiratory failure requiring mechanical ventilation: results of RARICO study. Chronic Obstr Pulm Dis. 2026; 13(6): 513-522. doi: http://dx.doi.org/10.15326/jcopdf.2026.0804
|
|